Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-7194

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-7194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended Release Tablets 50mg

CAUTION: Federal law prohibits transfer of Desvenlafaxine Extended-Release Tablets 50mg to anyone other than the person for whom it was prescribed. Desvenlafaxine is an antidepressant medication used to treat major depressive disorder. This pill contains desvenlafaxine succinate and other ingredients, amounting to 50mg of the medication. The manufacturer of the medication is Breckenridge Pharmaceuticals, Inc. It is important to note the expiration date and lot number for proper usage. This information is useful for anyone who is prescribed Desvenlafaxine Extended-Release Tablets 50mg.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

This appears to be a report on the effects of renal and hepatic impairment on the pharmacokinetics (PK) of some substance(s). The report shows the geometric mean ratios (and their confidence intervals) for Cmax and AUC (two important pharmacokinetic parameters) for different levels of impairment compared to normal (reference). The report also includes data on the effects of gender and age on PK.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This text appears to be a statistical analysis of the change in Cmax and AUC levels for Ketoconazole, a CYP3A4 inhibitor, with respect to a reference. The increase in Cmax is 1.08 and the increase in AUC is 1.43. These values are represented as geometric mean ratios with a 30% confidence level. No further information or context is provided.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

This appears to be a graph displaying the estimated proportion of patients with relapse over time, with the x-axis showing the time to relapse in days from randomization and the y-axis showing the proportion of patients with relapse. The graph compares the relapse rates between Desvenlafarine Extended-Release Tablets (at a dose of 50mg) and Placebo. At the 10-day mark, the estimated proportion of patients with relapse is 10%. Beyond that, it is unclear what specific values or percentages are being represented by the graph.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

This is a graph showing the estimated proportion of patients with relapse over time (in days) from randomization. The graph compares Desvenlafaxine Extended-Release Tablets to Placebo, with percentages ranging from 20% to 50%. The x-axis denotes time and the y-axis term shows the estimated proportion of patients experiencing a relapse.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

This is not-available as the text is incomplete and doesn't provide enough context.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.